Dianthus Therapeutics (FRA:87E) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:87E Dianthus Therapeutics Inc FRA:87E
30 GF Score
Price €86.00
GF Value €2.47
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:87E
30GF Score
Dianthus Therapeutics Inc FRA:87E
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Dianthus Therapeutics (FRA:87E) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of €86.00 is trading 3381.8% above its estimated GF Value™ of €2.47. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:87E:

  • Short Ratio:
  • GF Value™: €2.47 vs. price of €86.00 (3381.8% above fair value)
  • GF Score™: 30/100 with 7 warning signs

No single metric tells the full story. See the FRA:87E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dianthus Therapeutics Business Description

Other Exchanges DNTH:USA87E:Germany
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
30GF Score

Get the complete analysis for FRA:87E

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€86.00
Price
€2.47
GF Value